English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/209836
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Molecular Diagnosis of Inherited Coagulation and Bleeding Disorders

AuthorsBastida, José María; Benito, Rocío; Lozano, Maria Luisa; Marín-Quilez, Ana; Janusz, Kamila; Martín-Izquierdo, Marta; Hernandez-Sánchez, Jesus M.; Palma-Barqueros, Verónica; Hernández, Jesús M. ; Rivera, José; González-Porras, José R.
KeywordsMolecular diagnosis
Inherited platelet disorders
Inherited rare bleeding disorders
High-throughput sequencing
Issue Date2019
CitationSeminars in Thrombosis and Hemostasis 45(07): 695-707 (2019)
AbstractDiagnosis of inherited bleeding disorders (IBDs) remains challenging, especially in the case of inherited platelet disorders, due to the heterogeneity of the clinical and laboratory phenotype, the limited specificity of platelet function tests, and the large number of potential culprit genes. Unraveling the underlying molecular defect provides the definitive diagnosis of IBDs, facilitating prognosis and clinical care, which are especially important for severe clinical syndromes and those that may be associated with an increased risk of malignancy. Until recently, Sanger sequencing of candidate genes has been the only method of molecular diagnosis, but this approach is time-consuming and costly and requires phenotype-based identification of any obvious candidate gene(s). Nowadays, high-throughput sequencing (HTS) allows the simultaneous and rapid investigation of multiple genes at a manageable cost. This HTS technology that includes targeted sequencing of prespecified genes, whole-exome sequencing, or whole-genome sequencing, is revolutionizing the genetic diagnosis of human diseases. Through its extensive implementation in research and clinical practice, HTS is rapidly improving the molecular characterization of IBDs. However, despite the availability of this powerful approach, many patients still do not receive a diagnosis. As IBDs are complex and rare diseases, development of more advanced laboratory assays, improvements in bioinformatic pipelines, and the formation of multidisciplinary teams are encouraged to advance our understanding of IBDs.
Publisher version (URL)http://dx.doi.org/10.1055/s-0039-1687889
Appears in Collections:(CIC) Artículos
(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.